Catalyst Brief

← Calendar

Readoutin 44d

AstraZeneca — Anifrolumab (blinded)

Phase 3 primary completion: Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY).

Date
Jan 2027
Type
Readout
Indication
Systemic Sclerosis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from AstraZeneca

  1. May2027
  2. Feb2027
  3. Feb2027
  4. Feb2027
  5. Jan2027